Lempert N, MacDowell R T, Karmody A, Knight E, Cunningham T J, Sponzo R W, Horton J, Ruckdeschel J C
Cancer. 1979 May;43(5):1934-6. doi: 10.1002/1097-0142(197905)43:5<1934::aid-cncr2820430553>3.0.co;2-4.
Eleven bovine heterografts were utilized in the repetitive administration of chemotherapy in 10 patients with insufficient vascular access. Six grafts remained patent until the time of death and five grafts clotted from 71 to 1110 days postoperatively. Three patients are alive and well. All grafts were initially patent and no wound infections resulted. The bovine heterograft appears to be a useful adjunct for securing vascular access for patients requiring cancer chemotherapy.
11个牛异种移植物被用于10例血管通路不足患者的重复化疗给药。6个移植物直至患者死亡时仍保持通畅，5个移植物在术后71至1110天发生血栓形成。3例患者存活且状况良好。所有移植物最初均通畅，未发生伤口感染。牛异种移植物似乎是为需要癌症化疗的患者确保血管通路的一种有用辅助手段。
